|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 213/75 | |
| A61K 31/44 | |||
| A61P 7/02 |
| (11) | Number of the document | 2611779 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11757467.3 |
| Date of filing the European patent application | 2011-08-31 | |
| (97) | Date of publication of the European application | 2013-07-10 |
| (45) | Date of publication and mention of the grant of the patent | 2016-08-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/050057 |
| Date | 2011-08-31 |
| (87) | Number | WO 2012/031017 |
| Date | 2012-03-08 |
| (30) | Number | Date | Country code |
| 201161454396 P | 2011-03-18 | US | |
| 379339 P | 2010-09-01 | US |
| (72) |
CAPODANNO, Vincent, R., US
CORCORAN, Liam, IE
McNEVIN, Michael, US
ARROYO, Itzia Zoraida, US
WENSLOW, Robert, M., US
BALL, Richard, G., US
MARGELEFSKY, Eric, L., US
MAHER, Timothy, K., US
PANDEY, Anjali, US
|
| (73) |
Portola Pharmaceuticals, Inc.,
270 East Grand Avenue Suite 22, South San Francisco, California 94080,
US
|
| (54) | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR |
| CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR |